DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Induced Pluripotent Stem Cells as Potential Therapeutic Agents in NF1
Final rept. 1 May 2010-30 Apr 2010
INSTITUTE FOR CANCER RESEARCH PHILADELPHIA PA
Pagination or Media Count:
In this project, we are seeking to use induced pluripotent stem iPS cell technology as a potential therapy in NF1. In the first years, we have successfully produced iPS cells from fobroblasts from Nf1 -mice and characterized the properties of these cells, which include growth in clusters, expression of stem cell markers, normal karyotype, and the ability to form teratomas in mice. We also created a targeting gene-repair vector and have used this vector to to replace the defective Nf1 allele in these iPS cells. We then showed that we could differentiate iPS cells into Schwann-like cells in vitro, enabling drug sensitivity studies.
APPROVED FOR PUBLIC RELEASE